Crinetics Pharmaceuticals SEC Filings

Crinetics Pharmaceuticals insider sale by President & CEO Richard S. Struthers. The filing reports that on 09/26/2025 Mr. Struthers sold 4,000 shares of common stock in open-market transactions at $45.00 per share under a Rule 10b5-1 trading plan adopted August 30, 2024. The Form 4 lists his post-transaction beneficial holdings across direct and indirect holdings, including 320,017 shares held directly and multiple indirect holdings via family trusts and spouse (for example, 661,205 shares by Family Trust 1 and 106,000 shares indirect by Family Trust 2). The sale was effected automatically under the trading plan and was signed by an attorney-in-fact on 09/30/2025.

Crinetics Pharmaceuticals director Matthew K. Fust reported transactions on 09/26/2025. He exercised 10,000 stock options with a $1.91 exercise price and acquired 10,000 shares, and sold 16,000 shares in open-market transactions at $44.75 per share executed under a Rule 10b5-1 trading plan. After these transactions he beneficially owned 22,836 shares of common stock and held 10,000 stock options (with 2,092 derivative securities reported as beneficially owned following the transactions). The 10,000 options became exercisable per the stated vesting schedule; 1/3 vested on 02/16/2019 with monthly vesting thereafter.

Crinetics Pharmaceuticals (CRNX) filed a Form 144 notifying a proposed sale of 16,000 common shares through Morgan Stanley Smith Barney LLC on 09/26/2025 with an aggregate market value of $574,240.00. The filing shows the shares were acquired as 10,000 via exercise of stock options on 09/26/2025 (paid in cash) and 6,000 as restricted stock units on 06/07/2024. The company reports 94,175,994 shares outstanding and discloses no securities sold by the reporting person in the past three months. The filer certifies they are unaware of any undisclosed material adverse information.

Crinetics Pharmaceuticals, Inc. (CRNX) submitted a Form 144 notice for the proposed sale of securities. The filer intends to sell 4,000 shares of Common stock through UBS Financial Services Inc. (11 Madison Ave, New York) with an aggregate market value of $180,000. The approximate date of sale is 09/26/2025 on NASDAQ. The shares were acquired as Founder Shares from the issuer on 07/31/2011, and full payment was recorded on that date. The filing reports nothing to report for securities sold during the past three months. Other standard notice fields (such as a signed date of notice) are present as headers but no explicit signature date or contact details are provided in the text supplied.

Crinetics Pharmaceuticals announced that the U.S. Food and Drug Administration approved PALSONIFY™ (paltusotine) on September 25, 2025 for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY is described as a selectively-targeted somatostatin receptor type 2 nonpeptide agonist and is now the first once-daily, oral treatment approved for adults with acromegaly. Crinetics is also holding an investor conference call on September 25, 2025 to discuss the approval, and a press release and call replay will be available in the investors section of its website.

Farallon Capital and affiliated funds disclosed collective holdings in Crinetics Pharmaceuticals (CRNX). The Schedule 13G shows multiple Farallon funds and related entities beneficially own reported positions in the issuer's common stock. The largest single reported beneficial owner line is 5,625,098 shares (6.0% of the class) attributable to the group of Farallon Individual Reporting Persons acting with shared voting and dispositive power. Other reported aggregates include 5,482,921 shares (5.8%) for Farallon Partners, L.L.C. and 3,305,391 shares (3.5%) for Farallon Healthcare Partners Master, L.P. Each reporting person reports 0 sole voting power and varying shared voting/dispositive power. The filing is made under Section 240.13d-1(c) and includes signed certifications dated 09/08/2025.

Crinetics Pharmaceuticals (CRNX) reporting insider transactions by Dana Pizzuti. The filing shows on 09/02/2025 the reporting person acquired 5,000 shares of common stock by exercising options at an exercise price of $16.89 and simultaneously sold 5,000 shares in open-market transactions under a Rule 10b5-1 plan at a volume-weighted average price of $32.10 per share (range $32.00–$32.24). Following these transactions the reporting person beneficially owned 96,270 shares of common stock and directly held 84,042 shares underlying vested and unvested stock options that remain outstanding. The sale was effected automatically pursuant to a 10b5-1 trading plan adopted May 21, 2025.

Form 144 notice for Crinetics Pharmaceuticals, Inc. (CRNX) reports a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $154,950.00. The shares were acquired and will be paid for by exercise of stock options on 09/02/2025 and sale is expected the same date on NASDAQ. The filing also discloses recent 10b5-1 sales by Dana Pizzuti totaling 36,492 shares for gross proceeds of $1,102,425.82 executed on 08/20/2025 and 08/22/2025. The filer affirms no undisclosed material adverse information.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, executed transactions on 08/22/2025 reported on this Form 4. The filing discloses an exercise of a stock option to acquire 30,000 shares at an exercise price of $16.89 per share and an open-market sale of 30,000 shares executed under a Rule 10b5-1 trading plan adopted May 21, 2025.

The sale had a volume-weighted average price of $30.43 per share and a transaction-day price range of $30.00 to $30.98. Following the transactions the reporting person shows 66,270 shares beneficially owned directly and reports 30,000 underlying shares from the option; the Form lists 89,042 derivative securities beneficially owned following the reported transactions. The sale was effected automatically pursuant to the 10b5-1 plan.